Gynica to launch trial of cannabinoid-based endometriosis therapies

Israel-based Gynica will dose the first patient in a Phase I trial of its cannabinoid-based therapies IntraVagS301 and IntraVagS302 for endometriosis by the end of this year.

CEO Yotam Hod told the Clinical Trials Arena that the candidates will help alleviate patients’ symptoms of endometriosis, including chronic pelvic pain, dysmenorrhea (painful periods), and dyspareunia (painful intercourse).